## **SOMATIC VARIANT ANALYSIS REQUEST FORM – MULTI-GENE**

Sarah Cannon Molecular Diagnostics Ground Floor, Shropshire House 1 Capper Street, London WC1E 6JA



Part of HCA Healthcare UK

TEL: +44 (0)203 794 1920		EMAIL: <u>info@sarahcannon-md.co.uk</u> Web: <u>v</u>						ww.sarahcannon-md.co.uk		
FOR LABORATORY USE ONLY										
SCMD No:				red by: Received: (Date/Time)						
INDIVIDUAL AUTHORISING REQUEST (e.g. Clinician / Pathologist)										
Name:	Address:									
Phone:										
DESTINATION FOR ANALYSIS REPORT (ESSENTIAL – Results may be delayed if not completed)										
Name:		Address:								
Phone:										
Note: If as above pl				e tick here						
Required Method(s) for Report Delivery (please tick all that apply): Post $\square$ Fax $\square$ Email $\square$										
Results Fax number(s):				Results e-m	ail(s):					
INVOICING DETAILS (ESSENTIAL – Results may be delayed if not completed in full)										
Contact name:		Full Organisation Name and Postal Address:								
Phone:										
Email:		Note: An authorisa	tion	code is mandate	orv if pro	ovidina pi	rivate med	dical insura	nce details	
Note: An authorisation code is mandatory if providing private medical insurance details  PATIENT DETAILS (At least 3 unique identifiers are mandatory)										
Surname:		Forename:		•		DOB (DD/MM/YY):		YY):	Gender:	
									M 🗆 F 🗆	
Hospital Name: Surgical		al Case ID:		Hospital Number:			Requester Ref (if applicable):			
				-			-			
SAMPLE / PATHOLOGY DETAILS (Please provide as much information as possible)										
Material Supplied: (see website for tissue requirements) Estimated % of tumour nuclei (required for curls/DNA)										
FFPE Block Unstained		Slides		5-20%				51-75%		
Sections 'curls' Other:				21-50%			>75%			
Primary Tumour Site: Tumour S		Tumour Sub-Ty	ub-Type:		Tissue Sample Supplied:					
Address for return of FFPE block or other unused material:										
Note: If left blank, material will be returned to the same address as specified for the analysis report.										

## MGP-1: (22-gene panel)

AKT1, ALK, BRAF, CTNNB1, DDR2, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, KRAS, MAP2K1, MET, NOTCH1, NRAS, PIK3CA, PTEN, SMAD4, STK11, TP53

## MGP-2: (50-gene panel)

ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAS, GNAQ, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT,KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL

ANALYSIS REQUIRED (See website for full details of each assay)

## MGP-3 (small variants & fusions):

Small scale variants: AKT1, ALK, AR, BRAF, CDK4, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FGFR2, FGFR3, GNA11, GNAQ, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KIT, KRAS, MAP2K1, MAP2K2, MET, MTOR, NRAS, PDGFRA, PIK3CA, RAF1, RET, ROS1, SMO. Fusions: ALK, ROS1, RET (20 further fusion genes are also assessed for **research use only**, please see our website).